We are thrilled to share that Estrigenix Therapeutics has been awarded a phase 1 SBIR grant from the National Institute of Health. The one-year grant provides funds to support pre-clinical studies on one of Estrigenix’s lead compounds to reduce women’s suffering from the symptoms of menopause and lessen chances for dementia later in a woman’s life. The study is titled “Development of EGX358, an ER-beta Agonist to Treat Hot Flashes & Menopause-Related Memory Loss” and will be supported by the National Institute on Aging. The team of CEO William Donaldson, CSO Karyn Frick, and Vice President of Business Development Dan Sem have made significant progress during the last two years and is currently support by the MIDD for the preclinical characterization of their lead compound.